Clinical Performance of the Standard Q COVID-19 Rapid Antigen Test and Simulation of its Real-World Application in Korea
0
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
The rapid antigen test (RAT) for coronavirus disease (COVID-19) represents a potent diagnostic method in situations of limited molecular testing resources. However, considerable performance variance has been reported with the RAT. We evaluated the clinical performance of Standard Q COVID-19 RAT (SQ-RAT; SD Biosensor, Suwon, Korea), the first RAT approved by the Korean Ministry of Food and Drug Safety. In total, 680 nasopharyngeal swabs previously tested using real-time reverse-transcription PCR (rRT-PCR) were retested using SQ-RAT. The clinical sensitivity of SQ-RAT relative to that of rRT-PCR was 28.7% for all specimens and was 81.4% for specimens with RNA-dependent RNA polymerase gene (RdRp) threshold cycle (Ct) values ≤23.37, which is the limit of detection of SQ-RAT. The specificity was 100%. The clinical sensitivity of SQ-RAT for COVID-19 diagnosis was assessed based on the Ct distribution at diagnosis of 33,294 COVID-19 cases in Korea extracted from the laboratory surveillance system of Korean Society for Laboratory Medicine. The clinical sensitivity of SQ-RAT for COVID-19 diagnosis in the Korean population was 41.8%. Considering the molecular testing capacity in Korea, use of the RAT for COVID-19 diagnosis appears to be limited.
Abstract
The rapid antigen test (RAT) for coronavirus disease (COVID-19) represents a potent diagnostic method in situations of limited molecular testing resources. However, considerable performance variance has been reported with the RAT. We evaluated the clinical performance of Standard Q COVID-19 RAT (SQ-RAT; SD Biosensor, Suwon, Korea), the first RAT approved by the Korean Ministry of Food and Drug Safety. In total, 680 nasopharyngeal swabs previously tested using real-time reverse-transcription PCR (rRT-PCR) were retested using SQ-RAT. The clinical sensitivity of SQ-RAT relative to that of rRT-PCR was 28.7% for all specimens and was 81.4% for specimens with RNA-dependent RNA polymerase gene (RdRp) threshold cycle (Ct) values ≤23.37, which is the limit of detection of SQ-RAT. The specificity was 100%. The clinical sensitivity of SQ-RAT for COVID-19 diagnosis was assessed based on the Ct distribution at diagnosis of 33,294 COVID-19 cases in Korea extracted from the laboratory surveillance system of Korean Society for Laboratory Medicine. The clinical sensitivity of SQ-RAT for COVID-19 diagnosis in the Korean population was 41.8%. Considering the molecular testing capacity in Korea, use of the RAT for COVID-19 diagnosis appears to be limited.
참고문헌 (20)
- Options for the use of rapid antigen tests for COVID-19 in the EU, "EEA and the UK. Technical Report", European Centre for Disease Prevention and Control, 2020
- Ki Ho Hong, "Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea", Annals of Laboratory Medicine, 40(5), pp.351~360 (2020), 대한진단검사의학회[DOI]
- Iglὁi Z, "Clinical Evaluation of Roche SD Biosensor Rapid Antigen Test for SARS-CoV-2 in municipal health service testing site, the Netherlands", Emerg Infect Dis, 27, pp.1323~1329 (2021)
- Yamayoshi S, "Comparison of rapid antigen tests for COVID-19", Viruses, 12, pp.1420~ (2020)
- Victor M Corman, "Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study", The Lancet Microbe, 2(7), pp.e311~e319 (2021), Elsevier BV[DOI]
- Olearo F, "Handling and accuracy of four rapid antigen tests for the diagnosis of SARS-CoV-2 compared to RT-qPCR", J Clin Virol, 137, pp.104782~ (2021)
- Pray IW, "Performance of an antigen-based test for asymptomatic and symptomatic SARS-CoV-2 testing at two university campuses–Wisconsin, September–October 2020", MMWR Morb Mortal Wkly Rep, 69, pp.1642~1647 (2021)
- Cerutti F, "Urgent need of rapid tests for SARS CoV-2 antigen detection: evaluation of the SD-Biosensor antigen test for SARS-CoV-2", J Clin Virol, 132, pp.104654~ (2020)
- Mahase E, "Covid-19: Innova lateral flow test is not fit for “test and release” strategy, say experts", BMJ, 371, pp.m4469~ (2020)
- Wise J, "Covid-19: lateral flow tests miss over half of cases, Liverpool pilot data show", BMJ, 371, pp.m4848~ (2020)
- Deeks JJ, "Lateral flow tests cannot rule out SARS-CoV-2 infection", BMJ, 371, pp.m4787~ (2020)
- Schildgen V, "Limits and opportunities of SARS-CoV-2 antigen rapid tests–an experience-based perspective", Pathogens, 10, pp.38~ (2021)
- Burstyn I, "Towards reduction in bias in epidemic curves due to outcome misclassification through Bayesian analysis of time-series of laboratory test results: case study of COVID-19 in Alberta, Canada and Philadelphia, USA", BMC Med Res Methodol, 20, pp.146~ (2020)
- Huh Hee Jae, "Surveillance of Coronavirus Disease 2019 (COVID-19) Testing in Clinical Laboratories in Korea", Annals of Laboratory Medicine, 41(2), pp.225~229 (2021), 대한진단검사의학회[DOI]
- Scohy A, "Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis", J Clin Virol, 129, pp.104455~ (2020)
- Dinnes J, "Rapid, point‐of‐care antigen and molecular‐based tests for diagnosis of SARS‐CoV‐2 infection", Cochrane Database Syst Rev, 8, pp.CD013705~ (2020)
- Liotti FM, "Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen detection in nasopharynx samples", Clin Microbiol Infect, 27, pp.487~488 (2020)
- Lee S, "Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the Republic of Korea", JAMA Intern Med, 180, pp.1447~1452 (2020)
- Lee W, "COVID-19 in South Korea: epidemiological and spatiotemporal patterns of the spread and the role of aggressive diagnostic tests in the early phase", Int J Epidemiol, 49, pp.1106~1116 (2020)
- Wise J, "Covid-19: safety of lateral flow tests questioned after they are found to miss half of cases", BMJ, 371, pp.m4744~ (2020)